A panel at the SGO 2018 Annual Meeting on Women’s Cancer convened to achieve consensus on PARP inhibitor use for the treatment and maintenance of ovarian cancer in the context of current standards. READ MORE
A study soon to published found that palliative care for patients with ovarian cancer was often provided later than recommended in national guidelines.
Human epidermal growth factor receptor 2 may be a potential marker of poor prognosis in patients with unclassified ovarian cancer, according to a recent meta-analysis.
Researchers have developed an algorithm for differentiating between healthy women and those with ovarian cancer, as well as differentiating BRCA1 mutated-disease from wild-type disease.
A recent study compared the effects of the standard of care alone versus combining the standard treatment with a TKI for patients with recurrent epithelial ovarian cancer.